Anavex Life Sciences Corp (AVXL)

[sokol]

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. It is true Eisai has failed in its AD drug development. Therefore, is it logical that it would be looking for a new horse to ride if it has not given up on an AD drug, and why would it do that - give up?

Is it logical to assume Eiasi has abandoned any interest in AD? Eisai is listed on the Tokyo Stock Exchange among others. It is a prominent company in search of new drugs. As Xena has said Japan is ideal for approval of a drug as long as Anavex can approve the drug is safe. What’s more, Japan has an aging population - consider that and more. AD is a disease of the aging populations. Therefore, if Eisai is interested in Anavex (and I am always cautious about the interest of a competitor), that is an avenue to early approval of AVXL 2-73 in Japan at least, and it may be that investors that moved the market today may be inclined to agree.

However, let’s see what the next few days of trading bring although I think that it is very likely a lot of interest in Anavex stock will continue to develop between now and the middle of July. The big conference is coming up later this month. Companies will be interested in attracting attention for their AD drugs that are in development. AVXL 2-73 seems to me to be the new horse to ride for this year’s conference at least.